Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vitamin D and Breast Cancer Survival—In Reply

Vitamin D and Breast Cancer Survival—In Reply Letters In Reply We appreciate the thoughtful comments of Grube and mor progression, poor prognosis, drug resistance, and shorter 1 2,3 Cardenas in response to our recent article. patient survival. Concordantly, positive expression of sur- We agree with the observation that many commercial in- vivin has been associated with a significantly higher risk of re- surance plans do cover the cost of secobarbital for use in aid- currence and decreased overall survival rates in patients with in-dying. Of the 35 patients at our center participating in the breast cancer. Although it is described as a biomarker predic- Death With Dignity program who were prescribed secobarbi- tive of aggressive cancer, survivin has been corroborated to be tal between 2010 and 2016, 12 patients (34%), all of whom had the key player of a mechanism by which myocytes at risk of commercial insurance, received some degree of coverage for apoptosis retain their viability. Survivin myocardial expres- this medication. Copayments for these 12 patients ranged from sion after acute myocardial infarction (AMI) has been related $2.00 to $1236.26. The remaining 23 patients (66%) either to the survival of at-risk myocardium and to a more favorable chose to pay cash for the medication http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Vitamin D and Breast Cancer Survival—In Reply

Loading next page...
 
/lp/american-medical-association/vitamin-d-and-breast-cancer-survival-in-reply-RT3eCeDQp3
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2017.1477
Publisher site
See Article on Publisher Site

Abstract

Letters In Reply We appreciate the thoughtful comments of Grube and mor progression, poor prognosis, drug resistance, and shorter 1 2,3 Cardenas in response to our recent article. patient survival. Concordantly, positive expression of sur- We agree with the observation that many commercial in- vivin has been associated with a significantly higher risk of re- surance plans do cover the cost of secobarbital for use in aid- currence and decreased overall survival rates in patients with in-dying. Of the 35 patients at our center participating in the breast cancer. Although it is described as a biomarker predic- Death With Dignity program who were prescribed secobarbi- tive of aggressive cancer, survivin has been corroborated to be tal between 2010 and 2016, 12 patients (34%), all of whom had the key player of a mechanism by which myocytes at risk of commercial insurance, received some degree of coverage for apoptosis retain their viability. Survivin myocardial expres- this medication. Copayments for these 12 patients ranged from sion after acute myocardial infarction (AMI) has been related $2.00 to $1236.26. The remaining 23 patients (66%) either to the survival of at-risk myocardium and to a more favorable chose to pay cash for the medication

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 8, 2017

References